CombiGene – the gene therapy explorer
The goal for CombiGene is to develop treatment methods that can improve
the lives of milions of people all over the world.
Latest news from CombiGene
CombiGene and Cell and Gene Therapy Catapult sign agreement to develop manufacturing process for novel gene therapy to treat epilepsy
Collaboration between Cell and Gene Therapy Catapult (CGT Catapult) and Swed-ish gene therapy company CombiGene will take a unique therapy one step closer to helping sufferers of hard to treat epilepsy. Read more >> Combigene AB, Medicon Village,...
Another gene therapy product, Luxturna from Sparks Therapeutics, was approved December 19 by the FDA, the US food and drug regulatory authority. This clearly demonstrates what potential gene therapy has. Read more >> Combigene AB, Medicon Village,...
Study with brain tissue from human epilepsy patients confirms that brain cells express CombiGene’s candidate drug CG01
CombiGene has, in collaboration with Associate Professor David Woldbye at University of Copenhagen and Professor Merab Kokaia at Lund University, carried out a so-called ”human expression study”, i.e. a study using brain tissue from human epilepsy...
Developing new treatment methods for neurological diseases, with higher precision, greater efficacy and fewer side effects.
A STEP BY STEP TREATMENT
The focus for CombiGene is to produce a therapy for epileptic patients who cannot be helped by available medical treatments at present.
Read more »